.
.
.
.
Coronavirus

Swiss company Novartis to help make Pfizer-Biontech COVID vaccine

Published: Updated:

Swiss pharmaceuticals giant Novartis said Friday it had signed an initial agreement to help produce the Pfizer-BioNTech vaccine against COVID-19, as countries scramble to boost supplies.

The rare act of cooperation – in an industry usually marked by cut-throat competition – comes after French pharma group Sanofi announced earlier this week that it would also team up with rivals Pfizer and BioNTech to help produce 125 million doses of their jab.

For more coronavirus news, visit our dedicated page.

The two-dose vaccine, which is based on mRNA technology, has been shown to be around 95 percent effective and has been approved for use by the World Health Organization and in some 50 countries.

But it is in limited supply as nations around the world race to immunize their populations against the coronavirus, which has killed nearly 2.2 million people in just over a year.

Novartis said in a statement that it would use its sterilized manufacturing facilities at its site in Stein, Switzerland to help produce the Pfizer-BioNTech jabs.

The company's logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz, Switzerland, January 29, 2020. (Reuters)
The company's logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz, Switzerland, January 29, 2020. (Reuters)

Under the agreement, the company said it would “take bulk mRNA active ingredient from BioNTech and fill this into vials under aseptic conditions for shipment back to BioNTech for their distribution to healthcare system customers around the world.”

Once a final agreement is reached, Novartis said it expected to begin production in the second quarter of the year, with initial shipment of finished product expected in the third quarter.

Steffen Lang, Head of Novartis Technical Operations, stressed that the company was “committed to leverage our manufacturing capabilities to help support the supply of COVID-19 vaccines and therapeutics around the world.”

“We expect this to be the first of a number of such agreements,” he said in the statement.

Novartis said it was already in “advanced discussions” with a number of other companies about with other production tasks, including of mRNA, therapeutic protein and raw material production for COVID vaccines and therapeutics.

Read more:

After row with EU, AstraZeneca says fixed most of European manufacturing issues

EU will not budge after AstraZeneca offers 8 mln extra coronavirus vaccine shots

UK expects facilitation of its COVID-19 vaccine contracts: PM spokesman

Coronavirus: Why is it so hard to make COVID-19 vaccines and boost supplies?